NY-RT20

Each lot of NY-RT20 20mg is analyzed by reversed-phase high-performance liquid chromatography (HPLC) and released at ≥99% purity. Peptide identity is confirmed by mass spectrometry (MS), verifying the molecular weight of the peptide against its expected value.

• Purity: HPLC, ≥99% (lot-specific value reported on the COA)
• Identity: confirmed by mass spectrometry (MS)
• Presentation: lyophilized powder, 20 mg nominal per vial
• Reference data: lot-specific values reported on the accompanying COA

A Certificate of Analysis (COA) accompanies each lot and reports the measured purity and identity values for that specific batch.

These analyses are analytical characterizations of identity and purity only and do not assess biological activity, safety, or fitness for any application. For research use only, not for human use.

A Certificate of Analysis is available per production lot, documenting HPLC purity and mass-spectrometry identity confirmation.

View Certificates of Analysis →

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

References to clinical phases/studies describe the compound in independent third-party literature (e.g., ClinicalTrials.gov, PubMed) and do not represent claims, testing, or approval by NYsub Peptides.

NY-RT20 is a synthetic peptide characterized in the scientific literature as a single-molecule triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It belongs to the class of multi-receptor incretin-mimetic peptides studied in third-party laboratory metabolic research.

The 20 mg presentation supplied here is provided as a research chemical for in-vitro and laboratory use only. It has not been tested, validated, or approved by NYsub Peptides for any application, and no claim is made regarding biological effect. For research use only, not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

In the published literature, NY-RT20 has been studied as a tool compound for examining the pharmacology of multi-receptor incretin signaling. Reported third-party research lines associated with this class of peptide include:

• In-vitro characterization of GIP, GLP-1, and glucagon receptor binding, activation, and selectivity
• Study of downstream cyclic AMP (cAMP) signaling and receptor-mediated second-messenger pathways in cell-based assays
• Investigation of peptide structure–activity relationships for balanced multi-agonist design
• Comparative analytical studies of incretin-mimetic peptide stability and identity

These descriptions are provided for scientific context only and reflect published third-party research. This product is not for human use, diagnostic use, or therapeutic use.

Store the lyophilized peptide at -20°C in its sealed vial, protected from light and moisture, where it is stable for extended periods; refrigeration at 2-8°C may be used for short working intervals, avoiding repeated freeze-thaw cycles. Stability with bacteriostatic or sterile water has been characterized for laboratory reference only, under refrigerated storage within a limited window. Handle with appropriate PPE. Not for human use.

For Research Use Only · Not for human or veterinary use · Not for diagnostic or therapeutic use.

• General receptor-pharmacology literature describes GIP, GLP-1, and glucagon receptor signaling and multi-receptor (poly-agonist) peptide mechanisms in in-vitro models.
• Lot-specific analytical results (identity and purity) are documented on the accompanying Certificate of Analysis.

Supplied for laboratory research use only. Not for human use.